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ABSTRACT
Background: High blood pressure (BP) is common in acute stroke and associated
with a worse functional outcome. Glyceryl trinitrate (GTN), a nitric oxide donor, lowers
BP in acute stroke and may improve outcome.
Aims: RIGHT-2 tested the feasibility of performing a UK multicentre ambulance-based
stroke trial, and the safety and efficacy of GTN when administered by paramedics
before hospital admission.
Methods: Paramedic-led ambulance-based multi-centre prospective randomised
single-blind blinded-endpoint parallel-group controlled trial of transdermal GTN (given
for 4 days) versus sham in patients with ultra-acute (<4 hours) presumed stroke.
Data are number (%), median [interquartile range] or mean (standard deviation).
Results: Recruitment ran from October 2015 to 31st May 2018. 1,149 patients were
recruited from 8 UK Ambulance Services and taken to 54 acute hospitals. Baseline
characteristics include: mean age 73 (15) years; female 555 (48%); median time
from stroke to randomisation 70 [45, 115] minutes; Face-Arm-Speech scale score 2.6
(0.5); and blood pressure 162 (25)/92 (18) mmHg. The final diagnosis was ischaemic
stroke 52%, haemorrhagic stroke 13%, TIA 9%, and mimic 25%. The main trial
results will be presented in quarter 4 2018. The results will also be included in
updated Cochrane systematic reviews, and individual patient data meta-analyses of all
relevant randomised controlled trials.
Conclusion: It was feasible to perform a multicentre ambulance-based ultra-acute
stroke trial in the UK, and to treat with GTN versus sham. The relatively unselected
cohort of stroke patients is broadly representative of those admitted to hospital in the
UK.
Trial registration: ISRCTN26986053
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INTRODUCTION
Nitric oxide (NO) donors are candidate treatments for acute ischaemic and
haemorrhagic stroke.(1-3) NO is a cerebral and systemic vasodilator and so has the
potential for: improving cerebral perfusion and lowering blood pressure; modulating
vascular function through protecting endothelium and preventing smooth muscle cell
proliferation; modifying neuronal function, in part through acting as a
neurotransmitter; attenuating inflammation through reducing white cell function; and
inhibiting apoptosis. In preclinical studies of cerebral ischaemia, NO donors reduced
stroke lesion size, and improved regional cerebral blood flow (CBF) and functional
outcome.(4, 5) Two NO donors have been tested in small clinical studies of patients
with acute or recent stroke. Intravenous sodium nitroprusside (SNP) reduced BP,
attenuated platelet function, but did not alter CBF;(6) the antiplatelet effects suggest
that SNP should not be used in haemorrhagic stroke. In four pilot trials, transdermal
glyceryl trinitrate (GTN, nitroglycerin) lowered BP by approximately 8% (with later
effects attenuated by tachyphylaxis) and improved aortic vascular compliance; in
contrast, it had no effects on platelet function, middle cerebral artery blood flow
velocity or regional CBF.(7-10) Use of a transdermal preparation meant that the drug
was simple to administer and could be given to patients with dysphagia.
As a result of these data, the large international Efficacy of Nitric Oxide in Stroke
(ENOS) trial was performed in 4011 patients with acute stroke; GTN was safe to
administer but did not alter functional outcome.(11) However, in a pre-defined
subgroup, patients randomised within 6 hours of onset had improved functional
outcome,(12) a result mirrored by those from the small Rapid Intervention with
Glyceryl trinitrate in Hypertensive stroke Trial (RIGHT) where GTN was given within 4
hours of stroke onset (median onset-to-randomisation of 55 minutes) by paramedics
prior to hospital admission.(10) In an individual patient data meta-analysis of all of
these trials,(7-11) GTN was feasible to administer and safe.(13) Importantly,
treatment improved multiple outcomes if given within 6 hours, these including
significant reductions in dependency, disability, cognitive impairment, mood
disturbance, and death, and improved quality of life.(13)
High systolic blood pressure (SBP >140 mmHg) is present in 70% or more of patients
with acute stroke and is associated with a worse outcome (early recurrence, death
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within a few weeks, combined death and dependency after several months.(14-17)
Lowering BP might therefore reduce these events and improve functional outcome,
provided that cerebral perfusion is not critically reduced.
Taking account of the potential importance of lowering BP in acute stroke, the
antihypertensive properties of GTN, and potential benefit if given in the very early
hours after stroke, the phase III Rapid Intervention with Glyceryl trinitrate in
Hypertensive stroke Trial-2 (RIGHT-2) was run in the UK to test the safety and
efficacy of GTN.(18, 19) The study involved recruitment, consent and initial treatment
by paramedics at the scene with the aim of accelerating time to treatment. In a
second objective, RIGHT-2 assessed the feasibility of performing large multicentre
ambulance-based trials. Recruitment completed on 31st May 2018.
The aims of this paper are to present the baseline characteristics of included patients
and summarise issues with delivery of the trial.
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METHODS
Eligibility and consent
Details on the inclusion and exclusion criteria are given in the published protocol (18)
and in the latest version of the protocol (Appendix A). Trial-trained paramedics
considered all adult patients with suspected stroke they attended in the context of an
emergency 999 telephone call. Patients had to have a face-arm-speech time (FAST)
score of 2 or 3, be within 4 hours of symptom onset, and have systolic BP >120
mmHg. Patients with capacity (assessed using a short set of questions) gave written
informed consent at the stroke scene prior to enrolment. Patients lacking capacity
(e.g. due to drowsiness, dysphasia or confusion) had proxy consent given by a
relative, if present, or a paramedic at the scene. No screening logs were kept by
either participating paramedics or in ambulance.
Investigational medicinal product
The investigational medicinal product was transdermal GTN (5mg daily for four days,
Transiderm Nitro “5” Novartis Pharmaceuticals Ltd, UK).(18) In the absence of
matching placebo patches, patients randomised to the control group received a sham
dressing of similar size and look to the GTN patch (DuoDERM – a hydrocolloid
dressing, ConvaTec Ltd, UK). Patches and plasters came individually packed in
sachets; four sachets were placed within a larger plastic box (treatment pack) that
also contained a Patient Information Sheet, Consent Form and ambulance Case Report
Form. Packs were prepared by the Nottingham University Hospitals NHS Trust
Pharmacy.
Randomisation and data collection
Following consent, the paramedic opened the sealed treatment pack to enter a patient
into the study. After completing the baseline ambulance case report form, the
paramedic placed a patch/plaster on the patients back or shoulders.(18) Routine
ambulance-based procedures were performed in parallel, after which the patient was
then taken to hospital for further clinical management. The remaining three patches
or plasters were given daily on days 2-4.
Outcomes
The primary and main secondary outcomes were collected centrally on day 90 by a
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treatment-blinded assessor. Prior to this, they contacted the general practitioner to
check that the patient was still alive, and then telephoned the patient (or carer as
appropriate). Where telephone contact could not be made, outcome information was
collected via a postal questionnaire. Final diagnosis was determined from the local
investigator’s diagnosis, ideally at discharge from hospital or before this at day 4 or
on admission if discharge information was not available. The primary outcome was
dependency assessed using the modified Rankin Scale (mRS) at day 90.(18) The mRS
will be analysed across all 7 levels using ordinal logistic regression.(19) Secondary
outcomes include early events at day 4; and measures of disability (Barthel Index),
cognition (telephone-mini-mental state examination [t-MMSE], telephone interview for
cognitive status-modified [TICS-M]), mood (Zung depression scale) and quality of life
(Euro-QoL) at day 90; death. The effect of ambulance-administered GTN will be
assessed on brain scanning following hospital admission in patients with ischaemic
stroke (occluded artery, tissue hypoattenuation, lesion extent, swelling) and
intracerebral haemorrhage (haematoma size, intraventricular haemorrhage, swelling);
a research CT or MR scan on day 2 in some patients will allow progression of these
measures to be assessed. Safety outcomes included all-cause and cause-specific case
fatality; early neurological deterioration (based on change in NIHSS); hypotension
(SBP<90 mmHg) or hypertension (SBP>180 mmHg) during treatment; and serious
adverse events (all up to day 5, and fatal from day 5).(18)
Use of the internet
The RIGHT-2 trial used a secure internet site to collect data in real time on-line:
 Trial website: http://right-2.ac.uk
 Secure website for real time data entry and validation: https://www-
apache.nottingham.ac.uk/~nszwww/right-2/live/right-2_login.php
 Demo website for investigators to practise data entry: https://www-
apache.nottingham.ac.uk/~nszwww/right-2/demo/right-2_login.php
(log-in: demoinv1; password: nottingham; pin: 8888)
 Secure website for upload of brain scans
Funding and governance
Planning for RIGHT-2 commenced in 2014 following the results of the RIGHT and
ENOS trials of GTN.(10, 12) Funding for the trial was awarded by the British Heart
Foundation in September 2014.
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The trial was supervised by a Trial Steering Committee, run by a Trial Management
Committee (based in Nottingham UK), and was monitored by an independent Data
Monitoring Committee. By the end of recruitment, the DMC had met and assessed
safety and efficacy on 6 planned occasions; on each occasion they recommended
continuation of the trial. Independent experts adjudicated brain scans and serious
adverse events, blinded to treatment. An International Advisory Committee assisted
with advice on trial populations and the primary analysis.
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RESULTS
Trial delivery
Throughout the trial, 5 protocol amendments were made covering multiple issues.
Two key changes were made (in order of introduction):
1. Addition of a substudy exploring the experiences and perspectives of participating
paramedics
2. Increase in sample size from 850 (18) to 1050 and then 1100 patients reflecting
the presence of a higher than anticipated proportion of mimics (i.e. not stroke or
TIA, originally expected to be ~12% but in reality reaching 25%)
Additionally, a change to the plan on analysis of the mRS was introduced, again
because of the high mimic rate which would lead to a dilution of any treatment effect.
Rather than performing a shift analysis in all patients (intention to treat, ITT), a
hierarchical approach will be taken with the first analysis in the target population of
patients with a final diagnosis of stroke or TIA (i.e. excluding mimics), this amounting
to a modified ITT analysis. TIA is included since a positive treatment effect might be
associated with a change in diagnosis from mild stroke to TIA. If this modified ITT
analysis is statistically significantly positive, then the analysis will be performed in all
patients as per ITT. The proposal to change the method of analysis of the primary
outcome was presented to, and approved by, the Trial Steering Committee in April
2017, and subsequently by the International Advisory Committee; this decision was
made without knowledge of unblinded data. The final Statistical Analysis Plan was
submitted for publication in quarter 1 2018 prior to the planned unblinding of the data
in quarter 3 2018.(19) This plan supersedes the original intention given in the
published protocol.(18)
Baseline characteristics
The following data are given as number (%), median [interquartile range] or mean
(standard deviation, SD). 1149 participants were recruited between 22nd October
2015 and 23rd May 2018 (Figure 1) from 8 ambulance services (AS, 7 in England plus
Welsh AS) by 516 paramedics; these participants were taken to 54 hospitals.
The baseline clinical characteristics collected in the ambulance at the time of
randomisation are presented in Table 1. Key features include: mean age 72.5 (14.6)
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years; female 555 (48.3%); median time from onset to randomisation 70 [45, 115]
hours (Figure 2); face-arm-speech-time test 2.6 (0.5); and mean blood pressure
162.1 (25.1)/ 91.6 (17.9) mmHg. Further information was collected in hospital (when
treatment had already been administered) and this is shown in Appendix Table 1. This
division between baseline characteristics in the ambulance and hospital admission
characteristics is important because some hospital variables may have been
influenced by GTN if it alters outcome, e.g. stroke severity, stroke syndrome (20) and
final diagnosis of minor stroke versus TIA. At hospital, mean severity (National
Institutes of Health Stroke Scale, NIHSS) 9.5 (7.5); Glasgow coma score 13.9 (1.7);
and final diagnosis haemorrhagic stroke 144 (12.5%), ischaemic stroke 593 (52.0%),
TIA 108 (9.4%), mimic 283 (24.6%). When comparing patient characteristics by final
diagnosis, blood pressure was higher in haemorrhagic than ischaemic stroke (176/100
vs 161/90, p<0.0001). The mimic population (i.e. not stroke or TIA) included multiple
diagnoses, commonly related to a seizure/fit, migraine/headache, or
functional/psychosomatic disorder.
During the trial’s progress, a number of logistical issues arose (Appendix Table 2)
including the feasibility of ambulance services and hospitals joining the trial, consent
in ambulance and re-consent in hospital, availability and losses of IMP, and a cyber-
attack. Those related to consent and IMP management by paramedics will be
addressed specifically in a subsequent publication.
Appendix Table 3 shows univariate relationships between key baseline or hospital
admission factors, including year of randomisation into the trial. As the trial
progressed, time from onset to randomisation, and proportion of mimics (versus other
diagnoses) increased. Further, increasing time from onset to randomisation was
associated with less severe stroke (lower NIHSS) and proportion of strokes; higher
SBP was associated with increasing age, female sex and haemorrhagic stroke; and
increasing age was associated with being female, stroke severity, higher SBP, and a
longer time to randomisation.
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DISCUSSION
It was feasible to perform a multicentre ambulance-based ultra-acute stroke trial in
the UK, and to treat with GTN versus sham. The relatively unselected cohort of stroke
patients is broadly representative of those admitted to hospital in the UK. Following
completion of data validation, the database will be locked and the trial unblinded and
analysed. It is intended to present the main results in quarter 4 2018, with the main
manuscript published in parallel. Multiple pre-specified secondary publications and
analyses are planned and some are listed in the statistical analysis plan.
RIGHT-2 data will be shared with prospective individual patient data meta-analyses, in
particular the Blood pressure in Acute Stroke Collaboration (21) which encompasses
an update of trials of GTN for stroke (13) and an ongoing analysis of trials of BP
lowering in acute haemorrhagic stroke. Individual patient data will be shared with the
Virtual International Stroke Trials Archive;(22) ultimately, a subset of data will be
made available on the internet akin to the International Stroke Trial,(23) and
anonymised neuroimaging data will be published.(24) Summary data will be added to
updates of Cochrane Collaboration reviews.(25, 26)
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Table 1. Baseline ambulance characteristics of patients enrolled in the RIGHT-2 trial.
Data are number (%), median [IQR], or mean (standard deviation)
All HS IS TIA Mimic p
Patients 1149 144 597 108 283
Age (years) 72.5 (14.6) 73.2 (13.0) 75.1 (12.4) 73.2 (13.0) 66.3 (18.1) <0.0001
Sex, male (%) 594 (51.7) 81 (56.3) 310 (51.9) 62 (57.4) 132 (46.6) 0.14
OTR (hours) 70 [45,
115]
74 [45,
110]
66 [45,
107]
79 [49,
106]
75 [47,
126]
0.066
<=1 hour (%) 491 (42.7) 59 (41.0) 279 (46.7) 40 (37.0) 106 (37.5) 0.033
ECG
Sinus 659 (71.9) 92 (78.6) 320 (65.6) 61 (72.6) 178 (82.0) 0.0001
AF 187 (20.4) 15 (12.8) 128 (26.2) 15 (17.9) 26 (12.0) -
Other 71 (7.7) 10 (8.5) 40 (8.2) 8 (9.5) 13 (6.0) -
Systolic BP (mmHg) 162.1
(25.1)
176.0
(27.0)
160.6
(23.3)
161.3
(24.0)
159.1
(26.4)
<0.0001
Diastolic BP (mmHg) 91.6 (17.9) 100.1
(21.6)
90.0 (17.4) 91.6 (16.3) 90.7 (16.3) <0.0001
Heart rate (bpm) 82.2 (18.6) 81.5 (16.6) 82.7 (19.7) 78.3 (14.7) 83.4 (18.6) 0.091
Oxygen saturation
(%)
96.3 (2.8) 95.7 (3.1) 96.3 (2.8) 96.4 (2.3) 96.5 (2.8) 0.040
Temperature (°C) 36.5 (0.6) 36.4 (0.6) 36.5 (0.6) 36.6 (0.6) 36.7 (0.7) <0.0001
Glucose (mmol/L) 7.6 (3.4) 7.5 (3.3) 7.7 (3.5) 7 (2.6) 7.5 (3.4) 0.22
GCS [/15] 13.9 (1.7) 13.6 (1.8) 13.8 (1.7) 14.7 (0.8) 13.9 (1.8) <0.0001
<14 (%) 302 (26.4) 49 (34.0) 173 (29.0) 6 (5.6) 69 (24.6) <0.0001
FAST score [/3] 2.6 (0.5) 2.8 (0.4) 2.6 (0.5) 2.4 (0.5) 2.5 (0.5) <0.0001
=3 (%) 690 (60.2) 110 (76.4) 391 (65.5) 42 (38.9) 137 (48.6) <0.0001
Source of consent
(%)
Patient 603 (52.5) 60 (41.7) 281 (47.1) 84 (77.8) 169 (59.7) <0.0001
Relative 406 (35.4) 63 (43.8) 242 (40.5) 17 (15.7) 79 (27.9) -
Close friend 23 (2) 6 (4.2) 9 (1.5) 4 (3.7) 4 (1.4) -
Paramedic 116 (10.1) 15 (10.4) 65 (10.9) 3 (2.8) 31 (11.0) -
Enrolling AS (%)
East Midlands 218 (19) 25 (17.4) 121 (20.3) 21 (19.4) 46 (16.3) 0.12
East of England 178 (15.5) 23 (16.0) 89 (14.9) 13 (12.0) 53 (18.7) -
London 202 (17.6) 19 (13.2) 90 (15.1) 21 (19.4) 70 (24.7) -
South Central 7 (0.6) 1 (0.7) 5 (0.8) 0 (0) 1 (0.4) -
South-West 265 (23.1) 39 (27.1) 142 (23.8) 28 (25.9) 53 (18.7) -
Welsh 89 (7.7) 9 (6.3) 49 (8.2) 12 (11.1) 17 (6.0) -
West Midlands 37 (3.2) 4 (2.8) 20 (3.4) 2 (1.9) 10 (3.5) -
Yorkshire 153 (13.3) 24 (16.7) 81 (13.6) 11 (10.2) 33 (11.7) -
AS: Ambulance Service; BP: blood pressure; GCS: Glasgow coma scale; OTR: onset
to randomisation
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Figure 1. Recruitment throughout the trial.
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Figure 2. Histogram of time from onset to randomisation
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Appendix Table 1. Recorded patient characteristics at hospital admission. Data are
number (%), median [IQR], or mean (standard deviation)
All HS IS TIA Mimic p
Number of patients 1149 144 597 108 283
Ethnic group (%)
White 1014 (90) 128
(88.9)
543
(91.0)
98
(92.5)
244
(87.5)
0.27
Black 47 (4.2) 6 (4.2) 24 (4) 3 (2.8) 14 (5.0) -
Asian, east 42 (3.7) 5 (3.5) 19 (3.2) 4 (3.8) 14 (5.0) -
Asian, south-east 3 (0.3) 0 (0) 1 (0.2) 0 (0) 2 (0.7) -
Asian, south 2 (0.2) 2 (1.4) 0 (0) 0 (0) 0 (0) -
Asian, other 8 (0.7) 1 (0.7) 4 (0.7) 1 (0.9) 2 (0.7) -
Other 11 (1.0) 2 (1.4) 6 (1.0) 0 (0) 3 (1.1) -
Disposition (before stroke
onset) (%)
Home – independent 854 (75.6) 123
(86.6)
457
(76.5)
87
(81.3)
187
(66.1)
0.0005
Warden-aided flat 21 (1.9) 1 (0.7) 14 (2.3) 1 (0.9) 5 (1.8) -
Home – needing care 164 (14.5) 11 (7.7) 80
(13.4)
8 (7.5) 65
(23.0)
-
Carer’s home 14 (1.2) 0 (0) 10 (1.7) 1 (0.9) 3 (1.1) -
Respite care 4 (0.4) 0 (0) 2 (0.3) 0 (0) 2 (0.7) -
Residential home 30 (2.7) 4 (2.8) 14 (2.3) 6 (5.6) 6 (2.1) -
Care home 12 (1.1) 2 (1.4) 6 (1.0) 3 (2.8) 1 (0.4) -
Nursing home 8 (0.7) 0 (0) 5 (0.8) 1 (0.9) 2 (0.7) -
Rehabilitation hospital 3 (0.3) 0 (0) 2 (0.3) 0 (0) 1 (0.4) -
Other 20 (1.8) 1 (0.7) 7 (1.2) 0 (0) 11 (3.9) -
Pre-morbid mRS [/6] 0 [0, 2] 0 [0, 1] 0 [0, 2] 0 [0, 2] 1 [0, 3] 0.0005
>2 (%) 223 (19.7) 17
(11.8)
107
(17.9)
19
(17.6)
79
(27.9)
0.0002
Pre-morbid EuroQol–5D * 0.7 (0.3) 0.6 (0.4) 0.8 (0.3) 0.8 (0.3) 0.7 (0.3) <0.0001
Medical history (%)
Hypertension 643 (57.1) 82
(57.3)
355
(59.5)
64
(59.8)
142
(51.1)
0.12
Diabetes mellitus 227 (20.1) 22
(15.4)
125
(20.9)
19
(17.8)
61
(21.9)
0.37
Atrial fibrillation 234 (20.8) 23
(16.1)
147
(24.6)
17
(15.9)
47
(16.8)
0.010
Previous stroke 272 (24.2) 27
(18.9)
137
(22.9)
22
(20.6)
85
(30.6)
0.022
Previous TIA 177 (15.8) 14 (9.9) 76
(12.8)
30
(28.3)
56
(20.3)
<0.0001
Ischaemic heart disease 196 (17.5) 16
(11.3)
103
(17.3)
19
(17.8)
58
(21.1)
0.10
Peripheral arterial disease 19 (1.7) 2 (1.4) 10 (1.7) 3 (2.8) 4 (1.5) 0.81
Family history of young
stroke
12 (1.3) 0 (0) 10 (2.0) 0 (0) 2 (0.9) 0.18
BP lowering medication 560 (50.3) 62
(44.6)
317
(53.5)
57
(53.3)
124
(45.1)
0.054
Lipid lowering medication 444 (39.9) 49
(35.3)
226
(38.2)
48
(44.9)
121
(44.0)
0.18
Nitrate therapy 58 (5.2) 3 (2.2) 32 (5.4) 6 (5.6) 17 (6.2) 0.36
Smoking, current 168 (18.2) 9 (9.1) 91
(17.8)
14
(16.3)
54
(23.7)
0.043
Alcohol intake, >21 upw 57 (6.6) 7 (7.1) 38 (7.9) 4 (5.2) 8 (3.8) 0.037
Qualifying event (%)
Intracerebral haemorrhage 144 (12.5) 144
(100)
0 (0) 0 (0) 0 (0) -
Ischaemic stroke 597 (52.0) 0 (0) 597
(100)
0 (0) 0 (0) -
Stroke type unknown 1 (0.1) 0 (0) 0 (0) 0 (0) 0 (0) -
TIA 108 (9.4) 0 (0) 0 (0) 108
(100)
0 (0) -
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Non-stroke / mimic 283 (24.6) 0 (0) 0 (0) 0 (0) 283
(100)
-
OCSP syndrome (%) (20)
Total anterior circulation 351 (33.5) 77
(55.0)
222
(37.9)
10
(10.8)
42
(18.4)
<0.0001
Partial anterior circulation 416 (39.7) 42
(30.0)
232
(39.6)
40
(43.0)
102
(44.7)
-
Lacunar 243 (23.2) 18
(12.9)
114
(19.5)
39
(41.9)
72
(31.6)
Posterior circulation 37 (3.5) 3 (2.1) 18 (3.1) 4 (4.3) 12 (5.3)
IV thrombolysis (%) 295 (26) 0 (0) 283
(47.4)
1 (0.9) 11 (3.9) <0.0001
Feeding status (%)
Normal diet 625 (56.5) 30
(21.3)
273
(46.2)
98
(94.2)
224
(83.3)
<0.0001
Soft diet 103 (9.3) 9 (6.4) 76
(12.9)
1 (1) 16 (5.9)
Nasogastric feed only 48 (4.3) 14 (9.9) 27 (4.6) 1 (1) 6 (2.2)
PEG feed only 4 (0.4) 1 (0.7) 2 (0.3) 0 (0) 1 (0.4)
Intravenous/subcutaneous
fluids only
148 (13.4) 35
(24.8)
106
(17.9)
0 (0) 7 (2.6)
Nothing 178 (16.1) 52
(36.9)
107
(18.1)
4 (3.8) 15 (5.6)
Systolic blood pressure
(mmHg)
155.5
(25.8)
169.1
(27.2)
154.7
(23.6)
151.4
(26.4)
151.7
(27.1)
<0.0001
Diastolic blood pressure
(mmHg)
83.7 (16.2) 90.6
(18.8)
82.6
(15.6)
83.1
(15.5)
82.8
(15.4)
<0.0001
Heart rate (bpm) 79.4 (17.9) 77.9
(16.4)
80.4
(18.9)
77.9
(16.9)
78.5
(16.4)
0.25
Glucose (mmol/L) 7.5 (3.3) 7.5 (3.3) 7.7 (3.2) 6.8 (2.7) 7.3 (3.6) 0.074
Temperature (°C) 36.4 (0.6) 36.3
(0.7)
36.4
(0.5)
36.4
(0.5)
36.5
(0.6)
0.0010
Weight (kg) 74.1 (17.4) 72.7
(15.2)
74.7
(18.2)
76.2
(17.1)
72.5
(16.3)
0.24
Glasgow coma scale [/15] 13.8 (2.1) 12.3
(3.3)
13.8
(1.8)
14.8
(0.5)
14.3
(1.6)
<0.0001
NIHSS (/42) 9.5 (7.5) 15.4
(7.2)
10.6
(7.2)
2.9 (3.3) 5.6 (5.8) <0.0001
BP lowering drugs (%)
ACE-I 248 (21.6) 23
(16.0)
140
(23.5)
25
(23.1)
60
(21.2)
0.26
Angiotensin receptor
antagonist
105 (9.1) 13 (9.0) 57 (9.5) 10 (9.3) 25 (8.8) 0.99
ß-receptor antagonist 266 (23.2) 23
(16.0)
166
(27.8)
25
(23.1)
52
(18.4)
0.0020
Calcium channel blocker 215 (18.7) 23
(16.0)
128
(21.4)
12
(11.1)
52
(18.4)
0.055
Diuretic 83 (7.2) 7 (4.9) 46 (7.7) 7 (6.5) 23 (8.1) 0.62
   α-receptor antagonist 41 (3.6) 3 (2.1) 24 (4.0) 4 (3.7) 10 (3.5) 0.74
Centrally acting 3 (0.3) 1 (0.7) 2 (0.3) 0 (0) 0 (0) 0.54
Other 30 (2.6) 3 (2.1) 14 (2.3) 4 (3.7) 9 (3.2) 0.76
Number taken, median 1 [0, 2] 0 [0, 1] 1 [0, 2] 1 [0, 1] 0 [0, 2] -
0 (%) 537 (47.8) 75
(52.4)
261
(43.9)
50
(46.7)
150
(54.0)
0.092
1 (%) 284 (25.3) 44
(30.8)
154
(25.9)
31
(29.0)
55
(19.8)
2 (%) 210 (18.7) 18
(12.6)
124
(20.8)
21
(19.6)
47
(16.9)
3 (%) 66 (5.9) 4 (2.8) 38 (6.4) 4 (3.7) 20 (7.2)
4+ (%) 27 (2.4) 2 (1.4) 18 (3.0) 1 (0.9) 6 (2.2)
CT/MRI scan, hospital report †
Normal/no presenting lesion
seen
571 (52.6) 0 (0) 292
(49.6)
86
(84.3)
193
(77.2)
<0.0001
IS, no HTI 264 (24.3) 0 (0) 259
(44.0)
2 (2) 3 (1.2)
IS, with HTI 8 (0.7) 0 (0) 7 (1.2) 0 (0) 1 (0.4)
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HS 141 (13) 139
(97.2)
0 (0) 0 (0) 2 (0.8)
Other 101 (9.3) 4 (2.8) 31 (5.3) 14
(13.7)
51
(20.4)
Imaging compatible with
clinical presentation
791 (80.5) 141
(99.3)
451
(84.1)
65
(67.0)
134
(65.0)
<0.0001
Mass effect 115 (10.7) 81
(57.9)
23 (3.9) 1 (1.0) 10 (4.1) <0.0001
Cerebral atrophy 250 (23.4) 27
(19.7)
160
(27.3)
21
(20.4)
41
(17.1)
0.0077
Periventricular lucency 211 (19.7) 26
(19.0)
126
(21.4)
21
(20.6)
38
(15.8)
0.31
Previous stroke 273 (25.3) 28
(20.0)
144
(24.5)
27
(26.2)
73
(29.4)
0.21
BP: blood pressure; CT: computerised tomography; HS: haemorrhagic stroke; HTI:
haemorrhagic transformation; IS: ischaemic stroke; MRI: magnetic resonance
imaging; TIA: transient ischaemic attack
† Unadjudicated
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Appendix Table 2. Issues with delivery of the trial.
Issue Explanation Effect/response
Hospital feasibility A) Potential conflict with in-
hospital hyperacute studies or
commercial studies.
B) Reduced operational hours
due to imaging capacity
C) Delays in site setup.
A) Hospitals imposed recruitment time
restrictions (0800-1700 M-F / 2200-0600) or
withdrew part-way through the set-
up/recruitment phase to minimise loss of
recruitment to other hyperacute stroke
research studies
B) Out of hours imaging for non-urgent cases
not feasible, therefore trial operational hours
reduced to allow research imaging to be
completed
C) A few hospitals did not complete setup
phase despite interest from ambulance
services. Some paramedics had already
completed the trial training in these areas in
preparation
Ambulance service feasibility Limited capacity to deliver the
trial despite interest received
from hyperacute stroke centres
Limited capacity in some ambulance services
or concurrent studies led to non-participation
or participation in smaller localities.
Variation in ambulance service
operational delivery
Each ambulance trust operates
individually requiring specific
adjustments to ensure the trial
protocol was deliverable
Adjustments to data collection and local
accountability processes ensured feasibility of
trial delivery per ambulance service
Concurrent hyperacute
research
Delayed opening of hospital sites
due to concurrent cluster
randomised controlled trial
Co-enrolment discussed and agreed, some
hospital sites opted to wait until concurrent
trial has concluded
Half-point research accruals Research accrual point split
between recruiting ambulance
service and hospital
Due to two organisations involved in the
recruitment and continuation of care, the
recruitment accrual point was awarded
between hospital and ambulance service on
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an alternating basis. Many institutions found
this unsatisfactory
Prolonged IMP manufacture Internal department inspections
delayed production and Quality
Person check process prior to
IMP release
Delay in release of treatment packs to some
ambulance services thereby delaying
recruitment
Insufficient paramedics Work pressure, operational
demands
Addition of more ambulance stations and
hospitals within existing ambulance Services.
Addition of more ambulance services.
Explored participation of emergency medical
technicians; although probably feasible, this
was not pursued
Use of private ambulance
providers
Private ambulance companies
occasionally utilised to support
with frontline demand
Feasible, but did not progress to participation
Notification of recruitment Paramedic procedure to inform
trial coordination centre of
participant recruitment by
telephone
Notification of recruitment not always
received from recruiting paramedic due to
operational pressures. Some participants not
located at hospital due to unawareness of
enrolment
Participant conveyed to non-
participating hospital
Not every hyperacute stroke unit
within an ambulance service
area participated in RIGHT-2 due
to capacity and feasibility.
A few recruited patients were
taken to hospitals that were yet
to start-up
No treatment on days 2-4; no in-hospital data
available (but still available for follow-up at
days 90 and 365)
Recruitment of same patient
twice
Patient attended by different
paramedics at subsequent
emergency call
Single incidence; patient discontinued
treatment and follow-up
Apparent lack of consent in
ambulance when presenting to
hospital
Time pressure and severe stroke
severity
File notes confirmed consent obtained; MHRA
informed.
Mislaid IMP boxes Alternative procedures Temporary suspension of recruitment in one
ambulance service; majority of missing IMP
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found. MHRA informed. Accountability
procedure reviewed. Introduction of QR codes
on IMP to facilitate tracking of IMP using
smart-phones
Some hospitals do not allow
research coordinators to take
consent
CTIMP studies in some locations
require consultant continued
consent where proxy assent has
been gained by paramedics
Participants unable to give informed consent
in the ambulance due to lack of capacity;
relative, carer, friend or paramedic proxy
consent given at scene
Missed patches Patches on days 2, 3 and 4
omitted at weekends
Research staff often work within office hours,
contributing to delay in screening, continued
consent and often missed patches when
patients were recruited outside of working
hours, and especially on Bank Holidays
Holiday research cover Recruitment stopped and
restarted over holiday periods
Due to reduced research team cover a few
hospitals requested temporarily stopping
recruitment over Easter/Christmas/Bank
Holiday weekends. This led to confusion
among paramedics as to when they could
recruit
Hospital recruitment stop Four hospitals stopped receiving
patients prior to the end of
RIGHT-2 recruitment
Reduction in recruitment across local areas,
leading to a few patients being recruited to
closed hospitals in error
Participant transfers to non-
participating centre
Some neurointervention centres
not participating in RIGHT-2.
Patients unable to continue with randomised
treatment following transfer to non-
participating centre.
Cyber attack Cyber-attack of network hosting
trial database and website
Database unavailable for < 1 week; automatic
notifications not received by hospital staff
leading to a failure of alerts for two cases
Return of unused IMP at
closedown
<1% (14 out of 2800) treatment
packs not located by ambulance
services at trial closedown
A few IMP treatment packs were not located
at the ambulance station to which they were
originally assigned following recall after trial
closure. Ambulance service teams (including
make-ready departments as vehicles are
rotated) continue to search and remain
vigilant for the missing packs
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IMP: investigational medicinal product; MHRA: Medicines and Healthcare products Regulatory Agency
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Appendix Table 3. Univariate correlations between baseline characteristics. Correlations by point biserial or Spearman’s tests;
data are correlation coefficient and p value.
Male NIHSS Event SBP OTR Randomisation year
Age -0.12, <0.001 0.17, <0.001 0.19, <0.001 0.087, 0.003 0.073, 0.013 0.050, 0.089
Male X -0.048, 0.14 0.058, 0.053 -0.085, 0.004 -0.036, 0.220 0.018, 0.55
NIHSS X 0.28, <0.001 0.021, 0.529 -0.053, 0.108 0.003, 0.919
Event X 0.080, 0.007 -0.071, 0.017 -0.056, 0.058
SBP X -0.006, 0.840 0.015, 0.61
OTR X 0.11, <0.001
Event: haemorrhage stroke, ischaemic stroke, TIA, mimic; NIHSS: National Institutes of Health Stroke Scale (severity); OTR:
onset to randomisation; SBP: systolic blood pressure
